Form 4: Dyne Therapeutics Director Dirk Kersten Reports Stock Sales

Director Dirk Kersten reports sales of Dyne Therapeutics (DYN) stock through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported the sale of common stock on October 18, 2024, and October 21, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (FCF IV) on April 9, 2024.
• On October 18, 2024, 13,414 shares were sold at a weighted average price of $35.16.
• On October 21, 2024, 121 shares were sold at a price of $35.06.
• Kersten also indirectly holds shares through FCF IV and ForDyne B.V., but disclaims beneficial ownership except to the extent of his pecuniary interest.
• After the reported transactions, Kersten indirectly holds 73,104 shares through FCF IV and 5,795,364 shares through ForDyne B.V.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged plan, which is a common and legal practice. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is routinely monitored and reported, and sales under 10b5-1 plans are a common practice to avoid accusations of trading on non-public information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they perceive it negatively, although sales under 10b5-1 plans are generally viewed as routine.

Key Dates